文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

靶向中性粒细胞治疗冠状病毒病中的急性呼吸窘迫综合征

Targeting Neutrophils to Treat Acute Respiratory Distress Syndrome in Coronavirus Disease.

作者信息

Chiang Chih-Chao, Korinek Michal, Cheng Wei-Jen, Hwang Tsong-Long

机构信息

Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.

Puxin Fengze Chinese Medicine Clinic, Taoyuan, Taiwan.

出版信息

Front Pharmacol. 2020 Oct 9;11:572009. doi: 10.3389/fphar.2020.572009. eCollection 2020.

DOI:10.3389/fphar.2020.572009
PMID:33162887
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7583590/
Abstract

This review describes targeting neutrophils as a potential therapeutic strategy for acute respiratory distress syndrome (ARDS) associated with coronavirus disease 2019 (COVID-19), a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutrophil counts are significantly elevated in patients with COVID-19 and significantly correlated with disease severity. The neutrophil-to-lymphocyte ratio can serve as a clinical marker for predicting fatal complications related to ARDS in patients with COVID-19. Neutrophil-associated inflammation plays a critical pathogenic role in ARDS. The effector functions of neutrophils, acting as respiratory burst oxidants, granule proteases, and neutrophil extracellular traps, are linked to the pathogenesis of ARDS. Hence, neutrophils can not only be used as pathogenic markers but also as candidate drug targets for COVID-19 associated ARDS.

摘要

本综述描述了将中性粒细胞作为2019冠状病毒病（COVID-19）相关急性呼吸窘迫综合征（ARDS）的一种潜在治疗策略，COVID-19是由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的大流行病。COVID-19患者的中性粒细胞计数显著升高，且与疾病严重程度显著相关。中性粒细胞与淋巴细胞的比例可作为预测COVID-19患者ARDS相关致命并发症的临床标志物。中性粒细胞相关炎症在ARDS中起关键的致病作用。中性粒细胞作为呼吸爆发氧化剂、颗粒蛋白酶和中性粒细胞胞外陷阱的效应功能与ARDS的发病机制有关。因此，中性粒细胞不仅可作为致病标志物，还可作为COVID-19相关ARDS的候选药物靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a76/7583590/85b9a6224dfd/fphar-11-572009-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a76/7583590/0cd7b142dab5/fphar-11-572009-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a76/7583590/85b9a6224dfd/fphar-11-572009-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a76/7583590/0cd7b142dab5/fphar-11-572009-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a76/7583590/85b9a6224dfd/fphar-11-572009-g002.jpg

相似文献

[1]
Targeting Neutrophils to Treat Acute Respiratory Distress Syndrome in Coronavirus Disease.

Front Pharmacol. 2020-10-9

[2]
Neutrophil activation and neutrophil extracellular traps (NETs) in COVID-19 ARDS and immunothrombosis.

Eur J Immunol. 2023-1

[3]
Understanding the role of neutrophils in acute respiratory distress syndrome.

Biomed J. 2021-8

[4]
Neutrophils in COVID-19: recent insights and advances.

Virol J. 2023-8-2

[5]
A targetable 'rogue' neutrophil-subset, [CD11b+DEspR+] immunotype, is associated with severity and mortality in acute respiratory distress syndrome (ARDS) and COVID-19-ARDS.

Sci Rep. 2022-4-4

[6]
Role of Neutrophil Extracellular Traps in COVID-19 Progression: An Insight for Effective Treatment.

Biomedicines. 2021-12-23

[7]
Neutrophils during SARS-CoV-2 infection: Friend or foe?

Immunol Rev. 2023-3

[8]
Increased Peripheral Blood Neutrophil Activation Phenotypes and Neutrophil Extracellular Trap Formation in Critically Ill Coronavirus Disease 2019 (COVID-19) Patients: A Case Series and Review of the Literature.

Clin Infect Dis. 2022-2-11

[9]
High Levels of Neutrophil Extracellular Traps Persist in the Lower Respiratory Tract of Critically Ill Patients With Coronavirus Disease 2019.

J Infect Dis. 2021-5-20

[10]
A functionally distinct neutrophil landscape in severe COVID-19 reveals opportunities for adjunctive therapies.

JCI Insight. 2022-1-25

引用本文的文献

[1]
Predicting coronavirus disease 2019 severity using explainable artificial intelligence techniques.

Sci Rep. 2025-3-19

[2]
Different immunological characteristics of asymptomatic and symptomatic COVID-19 patients without vaccination in the acute and convalescence stages.

PeerJ. 2025-1-29

[3]
Neutrophil-to-lymphocyte ratio and short-term mortality in patients having anti-MDA5-positive dermatomyositis with interstitial lung disease: a retrospective study.

BMC Pulm Med. 2025-1-25

[4]
Deficient neutrophil responses early in influenza infection promote viral replication and pulmonary inflammation.

PLoS Pathog. 2025-1-17

[5]
Composition decipherment of Ficus pumila var. awkeotsang and its potential on COVID-19 symptom amelioration and in silico prediction of SARS-CoV-2 interference.

J Food Drug Anal. 2022-9-15

[6]
Testicular immunity.

Mol Aspects Med. 2024-12

[7]
Increased Circulating Extracellular Superoxide Dismutase Attenuates Platelet-Neutrophil Interactions.

Am J Respir Cell Mol Biol. 2025-6

[8]
The role of reactive oxygen species in severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection-induced cell death.

Cell Mol Biol Lett. 2024-11-8

[9]
Discovery of 1,3-disubstituted prop-2-en-1-one derivatives as inhibitors of neutrophilic inflammation via modulation of MAPK and Akt pathways.

J Enzyme Inhib Med Chem. 2024-12

[10]
Immunological and homeostatic pathways of alpha -1 antitrypsin: a new therapeutic potential.

Front Immunol. 2024

本文引用的文献

[1]
The SARS-CoV-2 Conserved Macrodomain Is a Mono-ADP-Ribosylhydrolase.

J Virol. 2021-1-13

[2]
Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series.

Mol Med. 2020-9-29

[3]
SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology.

J Exp Med. 2020-12-7

[4]
Neutrophil calprotectin identifies severe pulmonary disease in COVID-19.

J Leukoc Biol. 2021-1

[5]
Anakinra for severe forms of COVID-19.

Lancet Rheumatol. 2020-10

[6]
Recent insights for the emerging COVID-19: Drug discovery, therapeutic options and vaccine development.

Asian J Pharm Sci. 2021-1

[7]
Tocilizumab in patients with severe COVID-19: a retrospective cohort study.

Lancet Rheumatol. 2020-8

[8]
Anakinra for severe forms of COVID-19: a cohort study.

Lancet Rheumatol. 2020-7

[9]
Acute respiratory distress syndrome: a life threatening associated complication of SARS-CoV-2 infection inducing COVID-19.

J Biomol Struct Dyn. 2021-10

[10]
Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?

Int J Mol Sci. 2020-7-27

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索